Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Gene signature of residual risk following endocrine treatment in early breast cancer

A technology of endocrine therapy and endocrine therapy, applied in the direction of analytical materials, biomaterial analysis, special data processing applications, etc., can solve problems such as accelerating the development of stratification or targeted medicine

Active Publication Date: 2018-12-21
ONTARIO INST FOR CANCER RES OICR
View PDF14 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Nonetheless, despite more than a decade of development of multiple residual risk signatures, passing these tests has not significantly accelerated the development of stratified or targeted medicine
None of the Existing Tests Identify Actionable Targets That Could Form the Basis of a Next-Generation Stratified Medicine Approach

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gene signature of residual risk following endocrine treatment in early breast cancer
  • Gene signature of residual risk following endocrine treatment in early breast cancer
  • Gene signature of residual risk following endocrine treatment in early breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0101] Materials and methods

[0102] The TEAM trial is a multinational, open-label Phase III trial in which patients with hormone receptor-positive 19 Postmenopausal women with early breast cancer were randomly assigned to receive exemestane (25 mg) or tamoxifen (20 mg) once daily for the first 2.5 to 3 years; exemestane (25 mg) thereafter (total 5 years of treatment) (see Figure 11A ). Hormone-receptor (ER and PgR) and HER2 status assessed locally by immunohistochemistry to enter the trial, followed by central confirmation 28 , and confirmed HER2 status by immunohistochemistry and fluorescence in situ hybridization (FISH) 29 . According to ASCO / CAP guidelines 30-32 , to perform all evaluation work. None of the patients received anti-HER2 therapy. Distant recurrence-free survival (DRFS) was defined as the time from randomization to distant recurrence or death due to breast cancer 19 .

[0103] The TEAM trial included a pathology study consisting of 4,736 patients fr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

There is described herein a method of prognosing endocrine-only treatment in a subject with breast cancer, the method comprising: a) providing a tumor sample of the breast cancer; b) determining the expression level of at least 40 of the genes listed in Table 4 in the tumor sample; c) comparing said expression levels to a reference expression level of the group of genes from control samples from acohort of subjects; and d) determining the residual risk associated with the breast cancer; wherein a statistically significant difference or similarity in the expression of the group of genes compared to the reference expression level corresponds to a residual risk associated with breast cancer.

Description

[0001] Citations to related applications [0002] The present application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 263,805, filed December 7, 2015, which is incorporated herein by reference in its entirety. technical field [0003] The present disclosure generally relates to prognosing or classifying breast cancer subjects. More specifically, the present disclosure relates to methods and devices related to the use of biomarkers for the prognosis or classification of breast cancer subjects following endocrine therapy. Background technique [0004] Despite significant improvements in the treatment of early estrogen receptor positive (ER+) breast cancer, clinical problems remain. Mortality reduction with targeted antiendocrine therapy compared to previous 30-40 years 1,2 , but ER+ disease, which accounts for 80% of breast cancers, still accounts for the majority of deaths from early breast cancer 3 . Increasing use of multiparametric gene...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C40B40/06C12Q1/68C40B30/04G01N33/48G06F19/10G06F19/20
CPCG01N33/57415C12Q2600/158G01N2800/52C12Q1/6886G16H50/30C12Q2600/106C12Q2600/118
Inventor 简·巴亚尼约翰·木斯·巴特利特姚倩莉保罗·C·布特罗斯
Owner ONTARIO INST FOR CANCER RES OICR
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com